Irene Savelieva

Summary

Affiliation: St George's
Country: UK

Publications

  1. ncbi Rate versus rhythm control: is the debate over?
    A John Camm
    Department of Cardiological Sciences, St George s Hospital Medical School, London, UK
    J Interv Card Electrophysiol 7:7-11. 2002
  2. ncbi Atrial fibrillation and heart failure: natural history and pharmacological treatment
    Irina Savelieva
    Department of Cardiac and Vascular Sciences, St George's Hospital Medical School, Cranmer Terrace, London SW17 0RE, United Kingdom
    Europace 5:S5-19. 2004
  3. ncbi Anti-arrhythmic drug therapy for atrial fibrillation: current anti-arrhythmic drugs, investigational agents, and innovative approaches
    Irina Savelieva
    Division of Cardiac and Vascular Sciences, St George s University of London, Cranmer Terrace, London SW17 0RE, UK
    Europace 10:647-65. 2008
  4. ncbi Regulatory pathways for development of antiarrhythmic drugs for management of atrial fibrillation/flutter
    Irina Savelieva
    Division of Cardiac and Vascular Sciences, St George s University of London, London, UK
    Europace 13:1063-76. 2011
  5. ncbi Upstream therapies for management of atrial fibrillation: review of clinical evidence and implications for European Society of Cardiology guidelines. Part II: secondary prevention
    Irene Savelieva
    Division of Cardiac and Vascular Sciences, St George s University of London, London SW17 0RE, UK
    Europace 13:610-25. 2011
  6. ncbi Upstream therapies for management of atrial fibrillation: review of clinical evidence and implications for European Society of Cardiology guidelines. Part I: primary prevention
    Irene Savelieva
    Division of Cardiac and Vascular Sciences, St George s University of London, Cranmer Terrace, London SW17 0RE, UK
    Europace 13:308-28. 2011
  7. ncbi Primary and secondary prevention of atrial fibrillation with statins and polyunsaturated fatty acids: review of evidence and clinical relevance
    Irene Savelieva
    Division of Cardiac and Vascular Sciences, St George s University of London, Cranmer Terrace, London, SW17 0RE, UK
    Naunyn Schmiedebergs Arch Pharmacol 381:1-13. 2010
  8. ncbi Stroke in atrial fibrillation: update on pathophysiology, new antithrombotic therapies, and evolution of procedures and devices
    Irina Savelieva
    St George s University of London, London, United Kingdom
    Ann Med 39:371-91. 2007
  9. ncbi Some patients with paroxysmal atrial fibrillation should carry flecainide or propafenone to self treat
    A John Camm
    St George's, University of London, London SW17 0RE
    BMJ 334:637. 2007
  10. ncbi New antiarrhythmic drugs for atrial fibrillation: focus on dronedarone and vernakalant
    A John Camm
    Division of Cardiac and Vascular Sciences, St George s University of London, Cranmer Terrace, London, SW17 0RE, UK
    J Interv Card Electrophysiol 23:7-14. 2008

Collaborators

Detail Information

Publications24

  1. ncbi Rate versus rhythm control: is the debate over?
    A John Camm
    Department of Cardiological Sciences, St George s Hospital Medical School, London, UK
    J Interv Card Electrophysiol 7:7-11. 2002
  2. ncbi Atrial fibrillation and heart failure: natural history and pharmacological treatment
    Irina Savelieva
    Department of Cardiac and Vascular Sciences, St George's Hospital Medical School, Cranmer Terrace, London SW17 0RE, United Kingdom
    Europace 5:S5-19. 2004
    ....
  3. ncbi Anti-arrhythmic drug therapy for atrial fibrillation: current anti-arrhythmic drugs, investigational agents, and innovative approaches
    Irina Savelieva
    Division of Cardiac and Vascular Sciences, St George s University of London, Cranmer Terrace, London SW17 0RE, UK
    Europace 10:647-65. 2008
    ..However, despite exciting results from animal experiments and promising outcomes from retrospective analyses, there is no robust evidence of specific effects of these drugs to transform current clinical practice...
  4. ncbi Regulatory pathways for development of antiarrhythmic drugs for management of atrial fibrillation/flutter
    Irina Savelieva
    Division of Cardiac and Vascular Sciences, St George s University of London, London, UK
    Europace 13:1063-76. 2011
    ..The requirements for appropriate ancillary studies, including quality of life and left ventricular function assessment and cost-effectiveness analysis, have been identified. This article reports the discussions that were held...
  5. ncbi Upstream therapies for management of atrial fibrillation: review of clinical evidence and implications for European Society of Cardiology guidelines. Part II: secondary prevention
    Irene Savelieva
    Division of Cardiac and Vascular Sciences, St George s University of London, London SW17 0RE, UK
    Europace 13:610-25. 2011
    ..Part II of the review summarizes the evidence base for the use of upstream therapies for secondary prevention of AF...
  6. ncbi Upstream therapies for management of atrial fibrillation: review of clinical evidence and implications for European Society of Cardiology guidelines. Part I: primary prevention
    Irene Savelieva
    Division of Cardiac and Vascular Sciences, St George s University of London, Cranmer Terrace, London SW17 0RE, UK
    Europace 13:308-28. 2011
    ..This review provides a contemporary evidence-based insight into the role of upstream therapies in primary (Part I) and secondary (Part II) prevention of AF...
  7. ncbi Primary and secondary prevention of atrial fibrillation with statins and polyunsaturated fatty acids: review of evidence and clinical relevance
    Irene Savelieva
    Division of Cardiac and Vascular Sciences, St George s University of London, Cranmer Terrace, London, SW17 0RE, UK
    Naunyn Schmiedebergs Arch Pharmacol 381:1-13. 2010
    ..This review provides a contemporary evidence-based insight into the possible preventative and reverse remodeling role of statins and polyunsaturated fatty acids in AF...
  8. ncbi Stroke in atrial fibrillation: update on pathophysiology, new antithrombotic therapies, and evolution of procedures and devices
    Irina Savelieva
    St George s University of London, London, United Kingdom
    Ann Med 39:371-91. 2007
    ....
  9. ncbi Some patients with paroxysmal atrial fibrillation should carry flecainide or propafenone to self treat
    A John Camm
    St George's, University of London, London SW17 0RE
    BMJ 334:637. 2007
  10. ncbi New antiarrhythmic drugs for atrial fibrillation: focus on dronedarone and vernakalant
    A John Camm
    Division of Cardiac and Vascular Sciences, St George s University of London, Cranmer Terrace, London, SW17 0RE, UK
    J Interv Card Electrophysiol 23:7-14. 2008
    ....
  11. ncbi Treatment of atrial fibrillation
    Abhay Bajpai
    Ground Floor, Jenner Wing, St George s, University of London, Cranmer Terrace, Tooting, London SW170RE, UK
    Br Med Bull 88:75-94. 2008
    ..The presence of AF is associated with increased morbidity and mortality from stroke and heart failure, particularly in patients with structural heart disease...
  12. ncbi Update on atrial fibrillation: part I
    Irina Savelieva
    St George s University of London, Cranmer Terrace, London, U K
    Clin Cardiol 31:55-62. 2008
    ....
  13. ncbi Current strategies in the management of atrial fibrillation
    Marjan Jahangiri
    Department of Cardiac Surgery, St George s Hospital Medical School, London, United Kingdom
    Ann Thorac Surg 82:357-64. 2006
    ..Furthermore, in most series it is difficult to distinguish results of surgery for lone AF and AF associated with valvular heart disease and coronary artery disease...
  14. ncbi Advances in antiarrhythmic drug treatment of atrial fibrillation: where do we stand now?
    A John Camm
    St George s Hospital Medical School, London, United Kingdom
    Heart Rhythm 1:244-6. 2004
  15. ncbi Statins and polyunsaturated fatty acids for treatment of atrial fibrillation
    Irina Savelieva
    Division of Cardiac and Vascular Sciences, St George s University of London, London, UK
    Nat Clin Pract Cardiovasc Med 5:30-41. 2008
    ..This Review provides a contemporary evidence-based insight into the possible preventive and reverse remodeling roles of statins and polyunsaturated fatty acids in AF...
  16. ncbi Atrial pacing for the prevention and termination of atrial fibrillation
    Irina Savelieva
    St. Georges Hospital Medical School, London SW17 0RE, United Kingdom
    Am J Geriatr Cardiol 11:380-98. 2002
    ..The evolution of hybrid therapy, in which two or more different strategies are employed in the same patient, may be the most effective approach to management of AF...
  17. ncbi Update on atrial fibrillation: part II
    Irina Savelieva
    St George s University of London, London, UK
    Clin Cardiol 31:102-8. 2008
    ....
  18. ncbi Rationale and patient selection for "hybrid" drug and device therapy in atrial and ventricular arrhythmias
    A John Camm
    Department of Cardiological Sciences, St George s Hospital Medical School, Cranmer Terrace, London SW17 0RE, UK
    J Interv Card Electrophysiol 9:207-14. 2003
    ..Despite the lack of formal studies there is a very substantial clinical experience which testifies to the value of hybrid therapy for the management of both atrial fibrillation and ventricular tachycardia/fibrillation...
  19. ncbi The results of pacing trials for the prevention and termination of atrial tachyarrhythmias: is there any evidence of therapeutic breakthrough?
    Irina Savelieva
    Department of Cardiological Sciences, St George s Hospital Medical School, Cranmer Terrace, London SW1 0RE, United Kingdom
    J Interv Card Electrophysiol 8:103-15. 2003
    ..Dual chamber cardioverter-defibrillators with capacity to prevent and interrupt AF may offer more comprehensive and successful treatment for patients with advanced heart disease, frequent paroxysms of AF, and the risk of proarrhythmia...
  20. ncbi Current concepts in the pathogenesis of atrial fibrillation
    Antonios Kourliouros
    Department of Cardiac Surgery, St George s University of London, United Kingdom
    Am Heart J 157:243-52. 2009
    ..In addition, the interrelation between different mechanisms responsible for AF will be demonstrated, providing further insight into the complex pathophysiology...
  21. ncbi Heritability of QT interval: how much is explained by genes for resting heart rate?
    Chrysoula Dalageorgou
    Division of Clinical Developmental Sciences, St George s University of London, UK
    J Cardiovasc Electrophysiol 19:386-91. 2008
    ..We also studied the extent to which heritability of QT interval can be explained by genes that also influence resting heart rate...
  22. ncbi Novel If current inhibitor ivabradine: safety considerations
    Irina Savelieva
    St. George's University of London, London, UK
    Adv Cardiol 43:79-96. 2006
    ..Ivabradine has been associated with a good safety profile during its clinical development and its safety will be further assessed by postmarketing surveillance and during on-going clinical trials...
  23. ncbi Is there any hope for angiotensin-converting enzyme inhibitors in atrial fibrillation?
    Irina Savelieva
    Am Heart J 154:403-6. 2007
  24. ncbi Atrial fibrillation--all change!
    Irina Savelieva
    St George's University of London, London
    Clin Med 7:374-9. 2007